IndustryApril 2026
$420B Invested in AI Drug Discovery — 173 Programs in Clinic and Growing
Cumulative global investment in AI drug discovery exceeds $420 billion, with 173 programs in clinical development (94 Phase I, 56 Phase II, 15 Phase III). 15-20 AI-first programs are expected to enter pivotal trials in 2026, as regulators prepare AI-specific validation frameworks.
JFInnova Perspective
JFInnova operates at the exact intersection of these trends: AI-first drug design (scGPT + ESM-2), commercially validated VHH modality ($1B Cablivi), and a target (CD74) with convergent validation across multiple neurodegenerative diseases. Market timing could not be better.
References
2
AI Drug Discovery Attracts Billions in Funding
US Tech Times · 2026
3
AI, CRISPR, and mRNA Driving Biotech's Smartest Decade Yet
BioPharm International · 2026
AI drug discovery investment clinical